Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 701
- Registration Number
- NCT02596893
- Locations
- 🇺🇸
Texas Digestive Disease Consultants - Dallas, Arlington, Texas, United States
🇺🇸ClinSearch LLC, Chattanooga, Tennessee, United States
🇨🇦CHUS Hopital Fleurimont, Sherbrooke, Quebec, Canada
An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation
- Conditions
- Leukemia, MyeloidIsocitrate Dehydrogenase
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 319
- Registration Number
- NCT02577406
- Locations
- 🇹🇷
Local Institution - 874, Denizli, Turkey
🇹🇷Local Institution - 875, Gaziantep, Turkey
🇦🇺Local Institution - 904, Adelaide, South Australia, Australia
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Celgene
- Target Recruit Count
- 2494
- Registration Number
- NCT02576717
- Locations
- 🇺🇸
Local Institution - 110, Berkeley, California, United States
🇺🇸Local Institution - 123, Port Charlotte, Florida, United States
🇺🇸Local Institution - 179, Round Rock, Texas, United States
A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2017-12-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 624
- Registration Number
- NCT02556905
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷Hallym University Sacred Heart Hospital, Anyang, Korea, Republic of
🇰🇷Soon Chun Hyang University Hospital Bucheon, Bucheon, Korea, Republic of
Treatment of Pancreatic Cancer With Abraxane
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 317
- Registration Number
- NCT02555813
- Locations
- 🇦🇹
LKH Feldkirch, Feldkirch, Austria
🇦🇹KH Krems, Krems, Austria
🇦🇹LKH Leoben, Leoben, Austria
Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 127
- Registration Number
- NCT02555839
- Locations
- 🇦🇹
AKH, Universitätsklinik für Innere Medizin I /Klin. Abteilung für Onkologie, Vienna, Austria
🇦🇹LKH Feldkirch, Intern E, Hämatologie, Feldkirch, Austria
🇦🇹SCRI-CCCIT gemeinnützige GmbH & Universitätsklinikum der PMU Salzburg Gemeinnützige Salzburger Landeskliniken BetriebsgmbH, Salzburg, Austria
Abraxane in Treatment of Metastatic Breast Cancer
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Celgene
- Target Recruit Count
- 203
- Registration Number
- NCT02555696
- Locations
- 🇦🇹
Medical University Innsbruck, Innsbruck, Austria
🇦🇹LKH Salzburg, Salzburg, Austria
🇦🇹KH SMZ Ost, Vienna, Austria
ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
- First Posted Date
- 2015-09-16
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 20
- Registration Number
- NCT02551185
- Locations
- 🇺🇸
Pinnacle Oncology Hematology, Scottsdale, Arizona, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 100
- Registration Number
- NCT02546986
- Locations
- 🇺🇸
Palo Verde Hematology Oncology, Glendale, Arizona, United States
🇺🇸UCLA Hematology Oncology, Los Angeles, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 17
- Registration Number
- NCT02538965
- Locations
- 🇺🇸
Children's Hospital, Birmingham, Alabama, United States
🇺🇸Miller Children's Hospital, Long Beach, California, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States